Bernstein lowered the firm’s price target on Arrowhead (ARWR) to $24 from $27 and keeps a Market Perform rating on the shares. The company’s fiscal Q4 update centered primarily on
Bernstein lowered the firm’s price target on Arrowhead (ARWR) to $24 from $27 and keeps a Market Perform rating on the shares. The company’s fiscal Q4 update centered primarily on
Arrowhead Pharmaceuticals, Inc. (ARWR) has disclosed a new risk, in the Sales & Marketing category. The reliance of Arrowhead Pharmaceuticals, Inc. on Vanscoy Rare Pharmacy for the distribution of plozasiran
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1. STOCK NEWS: Dell (DELL) traded down post earnings as reported revenue
ההסכם עם Arrowhead (ARWR) מספק גיוון פלטפורמה והשקעה ברורה לטווח ארוך באסטרטגיות למחלות נדירות. הוא גם מגוון את התחומים הטיפוליים, מכסה בעיות שרירים, מערכת העצבים המרכזית ומצבים הקשורים לריאות, לפי
Needham lowered the firm’s price target on Sarepta (SRPT) to $202 from $205 and keeps a Buy rating on the shares. The deal with Arrowhead (ARWR) offers platform diversification with